Physician profile
Karnail S Dhillon
NPI 1437257961
$419.98
in general payments reported to CMS, 2019-2025
10 companies · $77.13 in 2025
The $77.13 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2021: $24.29 · 2022: $20.03 · 2023: $19.33 · 2024: $18.74 · 2025: $77.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $224.43 | 2019 | |
| Vanda Pharmaceuticals INC. | $38.33 | 2025 | Fanapt |
| Abbvie INC. | $24.29 | 2021 | |
| Neurocrine Biosciences, INC. | $22.88 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.51 | 2025 | Caplyta |
| Abbott Laboratories | $20.03 | 2022 | |
| Almatica Pharma LLC | $19.33 | 2023 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $18.74 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $16.29 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karnail Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.